Kent Hoskins, MD
Medical Oncology · Rockford, ILNPI 1255363529
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $801 of the $927 with a category attached, or 86.4%. 14 manufacturers reported payments, led by AstraZeneca at 30.8% of the total. Reporting peaked in 2024 at $407 and has fallen 86.5% since, to $55 in 2025. That places this record below the midpoint for medical oncology clinicians in IL, where the typical reported total is $1,059.
Across 30 payments — averaging $30.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$286
- Lilly USA, LLC$201
- Seagen Inc.$98
- Genentech USA, Inc.$74
- Gilead$50
- Merck$42
- plus $175 from 8 others
Across 88 payments — averaging $6311.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$233K
- Novartis$177K
- AbbVie$59K
- Pfizer$41K
- Genentech, Inc.$27K
- F. Hoffmann-la Roche AG$18K
What the payments were for
- Food & beverage$80186%
- Education$12614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $286 |
| Lilly USA, LLC | 5 | $201 |
| Seagen Inc. | 5 | $98 |
| Genentech USA, Inc. | 3 | $74 |
| Gilead | 3 | $50 |
| Merck | 2 | $42 |
| Puma Biotechnology, Inc. | 1 | $37 |
| Tactile Systems Technology Inc | 1 | $27 |
| Incyte Corporation | 1 | $22 |
| Beigene USA, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Morphosys, US Inc. | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $12 |
How this compares
$927 in reported general payments places this provider in the 45th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 26 | $386,123 |
| TukysaTucatinib | 12 | $298,210 |
| LynparzaOlaparib | 11 | $178,004 |
| IbrancePalbociclib | 12 | $176,119 |
| Exemestane | 17 | $3,703 |
| Letrozole | 105 | $1,172 |
| Anastrozole | 66 | $983 |
| Tamoxifen Citrate | 16 | $234 |
| Gabapentin | 20 | $211 |
| Baclofen | 11 | $98 |
| Potassium Chloride | 12 | $66 |
| Omeprazole | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $201 | $386,12326 claims |
| Seagen Inc.Tukysa | $98 | $298,21012 claims |
| AstraZenecaLynparza | $286 | $178,00411 claims |
| PfizerIbrance | $19 | $176,11912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Rockford
- Mete KorkmazRockford$5K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Nicklas PfanzelterGlenview$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.